Pricing Log in Create free account
Saturday 17 October 2026 Export RMD’s income statement to Excel — free account

ResMed Inc.

RMD Healthcare Medical Instruments & Supplies

ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025. In the quarter to June 2026, revenue grew 8.58%, EPS grew 2.32%, free cash flow fell 21.3% and total debt fell 39.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten, operating cash flow growth for three.

238.97 3.26 −1.35%
Market cap
$34.1B
P/E
22.8×
Fwd P/E
16.6×
Dividend yield
1.03%
F-score
6/9
Altman Z
10.00
Beneish M
−2.59
Dividend safety
96/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K
Auditor change
All filings →

Insider Decisions trades per month

Total sells 22.26
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 5 4 4 4 3 3 1 1 1 2 2 1
Insider Ownership 4.26%

Capital & Financial Ratios $m

Market Cap 34,070.00
Revenue 5,653.44
Net Income 1,523.29
Free Cash Flow 1,628.66
Net Debt (1,069.82)
Current Ratio 3.10 (at or above 1.5: strong)
Debt/Equity 0.06 (at or below 0.5: strong)
P/E ratio 22.85
Fwd P/E 16.60
P/S ratio 6.15
P/B ratio 5.28
Past 5Y EPS Growth 26.34% (at or above 15%: strong)
This Y EPS Growth 8.30%
Next Y EPS Growth 9.97%
Next Y revenue growth 2.66%
Next 5Y EPS Growth 9.23%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 6.0×, against a ten-year median of 6.9×; over the ten years it ranged from 4.3× in 2016 to 13.3× in 2021.
P/E against its own 10 years 6.78%
10-year low 10-year high
P/S against its own 10 years 34.65%
10-year low 10-year high
P/B against its own 10 years 14.85%
10-year low 10-year high
EV/Sales against its own 10 years 28.27%
10-year low 10-year high
EV/FCF against its own 10 years 17.66%
10-year low 10-year high

Dividends

Payout Ratio 0.24
Annual Dividend Rate 2.46
Annual Dividend Yield 1.03%
total individual payouts
2029 Powerpack
2028 Powerpack
2027 Powerpack
2026 2.43
0.60
0.60
0.66
2025 2.26
0.53
0.53
0.60
0.60
2024 2.02
0.48
0.48
0.53
0.53
2023 1.84
0.44
0.44
0.48
0.48
2022 1.72
0.42
0.42
0.44
0.44
2021 1.62
0.39
0.39
0.42
0.42
2020 1.56
0.39
0.39
0.39
0.39
2019 1.52
0.37
0.37
0.39
0.39
2018 1.44
0.35
0.35
0.37
0.37
2017 1.36
0.33
0.33
0.35
0.35
2016 1.26
0.30
0.30
0.33
0.33
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 2026
Cash 228 238 1,209 1,469
Receivables 705 837 939 1,036
Inventory 998 822 928 946
Other 405 — — 457
2,368 2,358 3,506 4,325
2023 2024 2025 2026
Payables 151 238 278 309
ST’ Debt — — — —
Other 504 — — 41
759 911 1,019 1,395

Compound Annual Growth %

10y 5y 3y
Sales 11.89% 12.08% 10.21%
Cash Flow 12.67% 19.64% 37.59%
Earnings 15.76% 26.27% 19.28%
Book Value 14.54% 17.94% 16.83%

Revenue $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 1,336 1,423 1,431 1,464 5,653
’25 1,225 1,282 1,292 1,348 5,146
’24 1,102 1,163 1,197 1,223 4,685
’23 950 1,034 1,117 1,122 4,223
’22 904 895 865 915 3,578
’21 752 800 769 876 3,197
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 457 340 554 455 1,806
’25 326 309 579 539 1,752
’24 286 273 402 440 1,401
’23 45 129 283 237 693
’22 (66) 220 117 79 351
’21 144 170 196 227 737
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Sep Dec Mar Jun Year
’26 — — — — —
’26 412 305 515 397 1,629
’25 306 285 555 505 1,651
’24 245 248 379 414 1,286
’23 12 97 251 199 559
’22 (97) 180 65 47 195
’21 125 132 167 196 620
Fiscal quarters ending in the months shown.

EPS $

Sep Dec Mar Jun Year
’26 — — — — —
’26 2.37 2.68 2.74 2.64 10.43
’25 2.11 2.34 2.48 2.58 9.51
’24 1.49 1.42 2.04 1.98 6.92
’23 1.43 1.53 1.58 1.56 6.09
’22 1.39 1.37 1.22 1.33 5.30
’21 1.22 1.23 (0.54) 1.33 3.24
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to June

Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Trend 2027e 2028e 2029e
Price, $
Price, $ Low 61.22 84.93 90.64 108.85 179.37 189.40 132.24 164.12 199.92 180.27

Analyst estimates 2027–2029

Powerpack
High 87.81 116.64 157.86 224.24 301.34 262.38 243.52 260.49 293.81 277.67
People
People Employees 6,080 5,940 7,240 7,770 7,970 8,160 10,140 9,980 10,600 11,370
Revenue/emp, $m 0.34 0.39 0.36 0.38 0.40 0.44 0.42 0.47 0.49 0.50
Income, $m
Income, $m Revenue 2,067 2,340 2,607 2,957 3,197 3,578 4,223 4,685 5,146 5,653
Gross margin, % 58.15 57.04 57.32 58.09 57.53 56.57 55.78 56.67 59.36 61.06
EBT 419 521 519 733 884 960 1,102 1,265 1,678 1,919
EBT margin, % 20.26 22.28 19.91 24.79 27.64 26.84 26.09 27.00 32.60 33.95
Net income 342 316 405 622 475 779 898 1,021 1,401 1,523
Depreciation 112 120 151 181 192 194 198 216 236 244
Per share, $
Per share, $ Revenue 14.62 16.39 18.21 20.49 22.00 24.50 28.77 31.87 35.08 38.85
Earnings 2.42 2.21 2.83 4.31 3.27 5.34 6.12 6.94 9.55 10.47
Cash flow 2.93 3.54 3.21 5.56 5.07 2.40 4.72 9.53 11.94 12.41
Capex (0.51) (0.50) (0.54) (0.73) (0.80) (1.07) (0.91) (0.78) (0.69) (1.22)
Free cash flow 2.42 3.04 2.67 4.82 4.27 1.34 3.81 8.75 11.25 11.19
Book value 13.87 14.42 14.48 17.30 19.86 23.01 28.14 33.08 40.68 45.25
Shares, m 141 143 143 144 145 146 147 147 147 146
Valuation, ×
Valuation, × P/E 32.18 46.75 43.73 44.55 75.39 39.33 35.76 26.94 27.02 18.63
P/S 5.33 6.33 6.79 9.37 11.21 8.56 7.59 5.87 7.36 5.02
P/B 5.62 7.20 8.55 11.10 12.41 9.11 7.76 5.65 6.34 4.31
EV/Sales 5.45 6.37 7.22 9.61 11.31 8.69 7.88 5.96 7.25 4.83
EV/FCF 32.88 34.36 49.31 40.81 58.35 159.46 59.49 21.72 22.59 16.76
Cash, $m
Cash, $m Operating cash flow 414 505 459 802 737 351 693 1,401 1,752 1,806
Capex (71) (71) (77) (106) (117) (156) (134) (115) (101) (177)
Free cash flow 343 434 382 696 620 195 559 1,286 1,651 1,629
Balance, $m
Balance, $m Working capital 1,284 554 589 921 663 1,242 1,609 1,447 2,486 2,930
Total debt 1,079 270 1,259 1,164 643 765 1,431 697 658 399
Net debt 257 81 1,112 701 348 492 1,203 459 (551) (1,070)
Shareholders’ equity 1,960 2,059 2,072 2,497 2,886 3,361 4,130 4,864 5,968 6,585
Returns, %
Returns, % ROA 10.18 9.66 11.28 14.30 10.19 15.87 15.15 14.99 18.62 17.77
ROIC 12.00 15.82 11.37 15.82 17.47 16.23 13.26 15.50 19.45 21.38
ROE 18.73 15.70 19.59 27.21 17.63 24.96 23.96 22.70 25.86 24.27
Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2026

Charts ten years each

ResMed Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BDX Becton, Dickinson and Company $52.8B 57.8× 37.7× +5.44% (above 0%: growing) −31.50% (below 0%: shrinking) −31.57% (below 0%: shrinking) 46.46% 13.31% Compare
MDLN Medline Inc. $48.1B — — +15.67% (above 0%: growing) — +3.42% (above 0%: growing) 28.82% 5.14% Compare
RMD ResMed Inc. $34.1B 22.8× 16.6× +8.58% (above 0%: growing) +2.32% (above 0%: growing) −21.31% (below 0%: shrinking) 58.84% 30.66%
ALC Alcon $32.1B 50.5× 31.0× +8.74% (above 0%: growing) n/m −0.54% (below 0%: shrinking) 59.33% 0.39% Compare
WST West Pharmaceutical Services, Inc. $27.0B 48.7× 37.3× +13.80% (above 0%: growing) +19.23% (above 0%: growing) −20.71% (below 0%: shrinking) 37.74% 20.53% Compare
SOLV Solventum Corporation $15.0B 10.4× 39.0× +2.22% (above 0%: growing) +1.92% (above 0%: growing) +144.07% (above 0%: growing) 58.22% 8.19% Compare
BAX Baxter International Inc. $13.3B — (loss-making) 44.7× +5.34% (above 0%: growing) +33.33% (above 0%: growing) +119.48% (above 0%: growing) 34.86% 7.33% Compare
RGEN Repligen Corporation $11.7B 234× 112× +11.93% (above 0%: growing) −65.38% (below 0%: shrinking) +27.10% (above 0%: growing) 53.91% 6.85% Compare
COO The Cooper Companies, Inc. $10.9B 19.8× 28.7× +0.56% (above 0%: growing) +357.14% (above 0%: growing) +65.96% (above 0%: growing) 66.77% 20.82% Compare
Median of peers $21.0B 49.6× 37.7× +7.09% +10.58% +15.26% 50.19% 7.76%

All 55 Medical Instruments & Supplies stocks →

RMD metrics, ten years each

ResMed Inc. (RMD) key facts

  • Strength: ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025.
  • Strength: Net income was $1.5 billion, or $10.47 per share (basic), a net margin of 26.9%.
  • ResMed Inc. (RMD) is a Medical Instruments & Supplies company in the Healthcare sector, listed on the New York Stock Exchange.
  • As of October 16, 2026, RMD traded at $238.97, a market capitalization of $34.1 billion.
  • At that price the stock trades at 22.8× trailing-twelve-month earnings and 6.2× sales; its P/E is higher than 7% of its own readings over the past ten years.
  • ResMed Inc. pays an annual dividend of $2.46 per share, a yield of 1.03%, with a payout ratio of 23.6%.
  • Return on equity was 24.3% and debt-to-equity 0.06.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 10.00 (safe zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.

ResMed Inc. (RMD) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/RMD · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com